Evidence map›Paper›PMID 33477970›Full record

ArticleCells2021

Unlike Its Paralog LEDGF/p75, HRP-2 Is Dispensable for MLL-R Leukemogenesis but Important for Leukemic Cell Survival.

Siska Van Belle, Sara El Ashkar, Kateřina Čermáková, Filip Matthijssens, Steven Goossens, Alessandro Canella, Courtney H Hodges, Frauke Christ, Jan De Rijck, Pieter Van Vlierberghe and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. HRP2 regulating MICU1-mediated CaNeoplasia (New York, N.Y.) · 2025
    Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Siska Van BelleLaboratory for Molecular Virology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Flanders, Belgium.
Sara El AshkarLaboratory for Molecular Virology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Flanders, Belgium.
Kateřina ČermákováInstitute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Flemingovo nam. 2, 166 10 Prague 6, Czech Republic.
Filip MatthijssensDepartment of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium.
Steven GoossensCancer Research Institute Ghent (CRIG), 9000 Ghent, Belgium.ORCID 0000-0002-5693-8570
Alessandro CanellaLaboratory for Molecular Virology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Flanders, Belgium.
Courtney H HodgesDepartment of Molecular & Cellular Biology, Center for Precision Environmental Health, and Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Frauke ChristLaboratory for Molecular Virology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Flanders, Belgium.
Jan De RijckLaboratory for Molecular Virology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Flanders, Belgium.
Pieter Van VlierbergheDepartment of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium.ORCID 0000-0001-9063-7205
Václav VeverkaInstitute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Flemingovo nam. 2, 166 10 Prague 6, Czech Republic.ORCID 0000-0003-3782-5279
Zeger DebyserLaboratory for Molecular Virology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Flanders, Belgium.ORCID 0000-0002-3982-1565
KU Leuven · BEGhent University · BEBaylor College of Medicine · USCharles University · CZCzech Academy of Sciences, Institute of Organic Chemistry and Biochemistry · CZ

Funding

Dynamic effects of cancer mutations on the mammalian SWI/SNF ATPase BrgR00CA187565 · NCI · BAYLOR COLLEGE OF MEDICINE · PI HODGES, HAMILTON COURTNEY · 2017 to 2019
$747k
NCI NIH HHS R00 CA187565
6 · The paper itself

Abstract

HDGF-related protein 2 (HRP-2) is a member of the Hepatoma-Derived Growth Factor-related protein family that harbors the structured PWWP and Integrase Binding Domain, known to associate with methylated histone tails or cellular and viral proteins, respectively. Interestingly, HRP-2 is a paralog of Lens Epithelium Derived Growth Factor p75 (LEDGF/p75), which is essential for

Indexed as

Adaptor Proteins, Signal TransducingAnimalsCarcinogenesisCell Cycle ProteinsCell SurvivalHEK293 CellsHistone-Lysine N-MethyltransferaseHumansLeukemiaMiceMice, KnockoutMyeloid-Lymphoid Leukemia ProteinTranscription FactorsAdaptor Proteins, Signal TransducingCell Cycle ProteinsHdgfl2 protein, mouseHistone-Lysine N-MethyltransferaseKMT2A protein, humanKmt2a protein, mouseMyeloid-Lymphoid Leukemia ProteinPSIP1 protein, humanTranscription Factorsanimal modelcell culturecell proliferationhematopoietic stem cellleukemiamolecular cell biologynuclear magnetic resonance (NMR)protein complexprotein-protein interaction

Identifiers

PMID33477970
PMCPMC7835958
OpenAlexW3122647193

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.